A wide range of psychedelics such as psilocybin and ayahuasca are now officially the lowest local law enforcement in the nation’s capital as of Monday.
Articles
Will Court Challenges Lead To Psychedelics Legalization?
A Seattle doctor is suing the DEA for blocking access to psilocybin. Could this be the quickest road to psychedelic drug legalization?
Whole-brain simulations hint at the neurobiological mechanisms underlying psychedelic-induced entropy
Scientists have used advanced computer simulations to better understand the neurobiological mechanisms underlying the psychedelic experience.
Survey Finds A Quarter Of Parkinson’s Patients Have Used Cannabis In The Last Six Months
Almost 25% of patients with Parkinson’s disease reported that they had used cannabis in the prior six months in a survey from the Parkinson’s Foundation.
Psychedelic drug users tend to have better overall physical health than non-users, study finds
The use of psychedelic substances is associated with better physical health, according to preliminary research published in the Journal of Psychopharmacology.
Wyoming Lawmakers Approve Marijuana Legalization Bill Sponsored By Top GOP Leaders
A Wyoming House committee on Friday approved a bill to legalize marijuana and briefly discussed a separate proposal to require state agencies to study and issue recommendations on allowing medical cannabis.
Psychedelic Drugs And The Placebo Effect
Part of the benefit from psychedelic medicine may actually be a Placebo Effect. Find out why that is actually a GOOD thing.
Mexican Congress Votes to Legalize Marijuana
Mexico’s Congress voted in favor of legalizing marijuana–a move some politicians claim will help curb the raging cartel violence.
Lifetime psychedelic use may reduce likelihood of hypertension
Lifetime classic psychedelic use, particularly tryptamines, may be linked to lower odds for hypertension in the previous year, according to data published in Hypertension.
Psychedelics research: Scientists zero in on the ideal dose of LSD to use in psychiatric treatment
New research published in Neuropsychopharmacology provides insight into the acute dose dependent effects of LSD.
MINDCURE (CSE: MCUR) (OTCQB: MCURF) Receives Unconditional Ethics Approval for its Psychedelic Integration Protocol Research Study
This approval is a key step forward in the development of the company's iSTRYM digital therapeutics platform
Cybin Announces API Synthesis and Optimization of Multiple Tryptamine Derivatives and Nomination of Two Deuterated Candidates for Full IND Enabling Studies Based on Second Milestone Achievement Pursuant to the Adelia Acquisition
Adelia Therapeutics, a subsidiary of Cybin Corp., achieves API synthesis and optimization on trypatmine derivatives.
WATCH - Mydecine Co-Founder Damon Michaels: It’s Time To Make Alternative Medicine Traditional Medicine
Damon Michaels, chief operating officer of emerging biotech and life sciences company Mydecine sat down with The Dales Report last week to discuss the company’s latest activity.
New York Lawmaker Files Bill To Decriminalize Psilocybin Mushrooms
A New York lawmaker is proposing to decriminalize psychedelic mushrooms in the state.
Numinus to expand state-of-the-art psychedelics research laboratory
Numinus expands its research lab, including more research space, supply capacity and accelerated IP development.